参考文献/References:
[1].Roger VL. Epidemiology of heart failure:a contemporary perspective[J]. Circ Res,2021,128(10):1421 -1434.
[2].Samson R,le Jemtel TH. Therapeutic stalemate in heart failure with preserved ejection fraction[J]. J Am Heart Assoc,2021,10(12):e021120.
[3].Shah SJ,Borlaug BA,Kitzman DW,et al. Research priorities for heart failure with preserved ejection fraction:national heart,lung,and blood institute working group summary[J]. Circulation,2020,141(12):1001-1026.
[4].Franssen C,Chen S,Unger A,et al. Myocardial microvascular inflammatory endothelial activation in heart failure with preserved ejection fraction[J]. JACC Heart Fail,2016,4(4):312-324.
[5].Ahmad A,Riaz Z,Sattar MA,et al. Effect of gasotransmitters treatment on expression of hypertension,vascular and cardiac remodeling and hypertensive nephropathy genes in left ventricular hypertrophy[J]. Gene,2020,737:144479.
[6].Zhao W,Chen Y,Yang W,et al. Effects of cardiomyocyte-specific deletion of STAT3—A murine model of heart failure with preserved ejection fraction[J]. Front Cardiovasc Med,2020,7:613123.
[7].DeBerge M,Shah SJ,Wilsbacher L,et al. Macrophages in heart failure with reduced versus preserved ejection fraction[J]. Trends Mol Med,2019,25(4):328 -340.
[8].Zhang X,Zheng C,Gao Z,et al. PKM2 promotes angiotensin‐Ⅱ‐induced cardiac remodelling by activating TGF‐β/Smad2/3 and Jak2/Stat3 pathways through oxidative stress[J]. J Cell Mol Med,2021,25(22):10711-10723.
[9].Parichatikanond W,Luangmonkong T,Mangmool S,et al. Therapeutic targets for the treatment of cardiac fibrosis and cancer:focusing on TGF-β signaling[J]. Front Cardiovasc Med,2020,7:34.
[10].Tan W,Li X,Zheng S,et al. A porcine model of heart failure with preserved ejection fraction induced by chronic pressure overload characterized by cardiac fibrosis and remodeling[J]. Front Cardiovasc Med,2021,8:677727.
[11].Roy C,Slimani A,de Meester C,et al. Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction[J]. J Cardiovasc Magn Reson,2018,20(1):55.
[12].Rush CJ,Berry C,Oldroyd KG,et al. Prevalence of coronary artery disease and coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction[J]. JAMA Cardiol,2021,6(10):1130-1143.
[13].Yang JH,Obokata M,Reddy YNV,et al. Endothelium-dependent and independent coronary microvascular dysfunction in patients with heart failure with preserved ejection fraction[J]. Eur J Heart Fail,2020,22(3):432-441.
[14].Wei J,Nelson MD,Sharif B,et al. Why do we care about coronary microvascular dysfunction and heart failure with preserved ejection fraction:addressing knowledge gaps for evidence-based guidelines[J]. Eur Heart J,2018,39(37):3451-3453.
[15].Konerman MC,Greenberg JC,Kolias TJ,et al. Reduced myocardial flow reserve is associated with diastolic dysfunction and decreased left atrial strain in patients with normal ejection fraction and epicardial perfusion[J]. J Card Fail,2018,24(2):90-100.
[16].van Tassell BW,Trankle CR,Canada JM,et al. IL-1 blockade in patients with heart failure with preserved ejection fraction[J]. Circ Heart Fail,2018,11(8):e005036.
[17].Zheng ZH,Zeng X,Nie XY,et al. Interleukin-1 blockade treatment decreasing cardiovascular risk[J]. Clin Cardiol,2019,42(10):942-951.
[18].Kolijn D,Pabel S,Tian Y,et al. Empagliflozin improves endothelial and cardiomyocyte function?in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation[J]. Cardiovasc Res,2021,117(2):495-507.
[19].Packer M,Butler J,Zannad F,et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction:EMPEROR-Preserved trial[J]. Circulation,2021,144(16):1284-1294.
[20].Kjeldsen SE,von Lueder TG,Smiseth OA,et al. Medical therapies for heart failure with preserved ejection fraction[J]. Hypertension,2020,75(1):23-32.
[21].Kasiakogias A,Rosei EA,Camafort M,et al. Hypertension and heart failure with preserved ejection fraction:position paper by the European Society of Hypertension[J]. J Hypertens,2021,39(8):1522-1545.
[22].Paz Ocaranza M,Riquelme JA,García L,et al. Counter-regulatory renin-angiotensin system in cardiovascular disease[J]. Nat Rev Cardiol,2020,17(2):116-129.
[23].Redfield MM,Anstrom KJ,Levine JA,et al. Isosorbide mononitrate in heart failure with preserved ejection fraction[J]. N Engl J Med,2015,373(24):2314 -2324.
[24].Zamani P,Tan V,Soto-Calderon H,et al. Pharmacokinetics and pharmacodynamics of inorganic nitrate in heart failure with preserved ejection fraction[J]. Circ Res,2017,120(7):1151 -1161.
[25].Gui Y,Chen J,Hu J,et al. Efficacy and safety of inorganic nitrate versus placebo treatment in heart failure with preserved ejection fraction[J]. Cardiovasc Drugs Ther,2020,34(4):503-513.
[26].Armstrong PW,Lam CSP,Anstrom KJ,et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction:the VITALITY-HFpEF randomized clinical trial[J]. JAMA,2020,324(15):1512-1521.
[27].Udelson JE,Lewis GD,Shah SJ,et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction[J]. JAMA,2020,324(15):1522-1531.
[28].Kolijn D,Kovács ?,Herwig M,et al. Enhanced cardiomyocyte function in hypertensive rats with diastolic dysfunction and human heart failure patients after acute treatment with soluble guanylyl cyclase(sGC) activator[J]. Front Physiol,2020,11:345.
[29].Leite S,Moreira-Costa L,Cerqueira R,et al. Chronic sildenafil therapy in the ZSF1 obese rat model of metabolic syndrome and heart failure with preserved ejection fraction[J]. J Cardiovasc Pharmacol Ther,2021,26(6):690-701.
[30].Borlaug BA,Lewis GD,McNulty SE,et al. Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction[J]. Circ Heart Fail,2015,8(3):533-541.
[31].Wang H,Anstrom K,Ilkayeva O,et al. Sildenafil treatment in heart failure with preserved ejection fraction[J]. JAMA Cardiol,2017,2(8):896-901.
[32].Lewis GA,Dodd S,Clayton D,et al. Pirfenidone in heart failure with preserved ejection fraction:a randomized phase 2 trial[J]. Nat Med,2021,27(8):1477-1482.
[33].Padro T,Manfrini O,Bugiardini R,et al. ESC working group on coronary pathophysiology and microcirculation position paper on ’coronary microvascular dysfunction in cardiovascular disease’[J]. Cardiovasc Res,2020,116(4):741-755.
[34].Marume K,Takashio S,Nagai T,et al. Effect of statins on mortality in heart failure with preserved ejection fraction without coronary artery disease—Report from the JASPER study[J]. Circ J,2019,83(2):357-367.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(5):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(5):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(5):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(5):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[8]高薇 陈伟.铁过载性心肌病[J].心血管病学进展,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
GAO WeiCHEN Wei.Iron Overload Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(5):680.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.006]
[9]何燕 刘育.C型利钠肽与心力衰竭[J].心血管病学进展,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
HE Yan,LIU Yu.C-type Natriuretic Peptide and Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):745.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.020]
[10]吴彤 高东来.心房颤动合并心力衰竭的射频消融治疗[J].心血管病学进展,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
WU TongGAO Donglai.Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):757.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.023]
[11]菲尔凯提·玉山江李昊穆叶赛·尼加提.射血分数保留性心力衰竭合并糖尿病的研究进展[J].心血管病学进展,2020,(4):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
FEIERKAITI·Yushanjiang,LIHao,MUYESAI.Nijiati.Heart Failure With Preserved Ejection Fraction and Diabetes Mellitus[J].Advances in Cardiovascular Diseases,2020,(5):373.[doi:10.16806/j.cnki.issn.1004-3934.2020.04.011]
[12]贾晓艳 安晋阳 彭可玲 刘永铭.可溶性鸟苷酸环化酶激动剂治疗射血分数保留性心力衰竭的研究进展[J].心血管病学进展,2022,(2):141.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.012]
JIA Xiaoyan,AN Jinyang,PENG Keling,et al.Soluble Guanylate Cyclase Stimulators in the Treatment of Heart Failure with Preserved Ejection Fraction[J].Advances in Cardiovascular Diseases,2022,(5):141.[doi:10.16806/j.cnki.issn.1004-3934.2022.02.012]